NDA 215383 · Merck Sharp Dohme
Welireg
Belzutifan · Oral · Hypoxia-inducible Factor Inhibitor
NovelPriority reviewOrphanCDER novel approval, Aug 13, 2021: To treat von Hippel-Lindau disease under certain conditions
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Aug 13, 2021
Approved uses
7
Original approval plus efficacy supplements
Registered trials
45
8 Phase 3, 14 recruiting
FAERS reports
1,777
1,224 serious, 167 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat von Hippel-Lindau disease under certain conditions
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 24, 2026 Supplement 13 · Efficacy LabelLetter
- Jun 12, 2026 Supplement 15 · Efficacy · priority review LetterLabel
- May 14, 2025 Supplement 12 · Efficacy · priority review OrphanLabelMedication GuideLetter
- Apr 15, 2025 Supplement 10 · Efficacy LetterLabel
- Apr 15, 2025 Supplement 11 · Efficacy LetterLabel
- Dec 14, 2023 Supplement 6 · Efficacy · priority review LabelMedication GuideLetter
- Aug 13, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelMedication GuideLetter
1 products under this application
- WELIREG · BELZUTIFAN 40MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Belzutifan" as an intervention, any sponsor and status, largest first.
- A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05239728 · 1,800 participants (planned) · Start Mar 15, 2022 · Primary completion Oct 28, 2026
Drug: Belzutifan; Pembrolizumab and 1 more · For: Carcinoma, Renal Cell
Sites: Phoenix, Arizona; Duarte, California; La Jolla, California · 285 sites in all
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04736706 · 1,688 participants · Start Apr 14, 2021 · Primary completion Feb 4, 2026
Drug: Pembrolizumab; Belzutifan and 2 more · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 262 sites in all
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02861573 · 1,200 participants (planned) · Start Nov 17, 2016 · Primary completion Oct 22, 2027
Drug: Pembrolizumab 200 mg; Olaparib 400 mg and 10 more · For: Metastatic Castration-Resistant Prostate Cancer
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07227402 · 904 participants (planned) · Start Nov 26, 2025 · Primary completion Feb 27, 2032
Drug: Belzutifan; Zanzalintinib and 1 more · For: Renal Cell Carcinoma
Sites: Anchorage, Alaska; Fullerton, California; Los Angeles, California · 129 sites in all
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07489495 · 758 participants (planned) · Start Apr 9, 2026 · Primary completion Nov 27, 2030
Drug: Belzutifan; Zanzalintinib and 1 more · For: Carcinoma, Renal Cell
Sites: Duarte, California; Irvine, California; Marietta, Georgia · 111 sites in all
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04195750 · 755 participants · Start Feb 27, 2020 · Primary completion Apr 15, 2024
Drug: Belzutifan; Everolimus · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; La Jolla, California; Santa Rosa, California · 172 sites in all
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04586231 · 747 participants · Start Feb 25, 2021 · Primary completion Feb 2, 2026
Drug: Belzutifan; Lenvatinib and 1 more · For: Carcinoma, Renal Cell
Sites: Chandler, Arizona; Los Angeles, California; Orange, California · 184 sites in all
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04976634 · 730 participants (planned) · Start Aug 18, 2021 · Primary completion Mar 22, 2027
Drug: Pembrolizumab; Belzutifan and 1 more · For: Neoplasm Malignant
Sites: Tucson, Arizona; Duarte, California; Los Angeles, California · 57 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaemia329
- malignant neoplasm progression262
- hypoxia174
- fatigue129
- death80
- dyspnoea70
- diarrhoea66
- haemoglobin decreased65
- off label use65
- oxygen saturation decreased61
- nausea59
- therapy interrupted57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 39 |
| 2022 | 315 |
| 2023 | 388 |
| 2024 | 179 |
| 2025 | 234 |
| 2026 | 622 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Welireg (Belzutifan)
2024 spending
$205M
Beneficiaries
1,896
7,964 claims
Per beneficiary
$108,365
$323.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $3,981,413 |
| 2022 | $29,705,807 |
| 2023 | $59,823,810 |
| 2024 | $205,460,496 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.